Last $3.76 USD
Change Today +0.05 / 1.35%
Volume 1.8M
ARRY On Other Exchanges
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

array biopharma inc (ARRY) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/4/13 - $6.07
52 Week Low
10/13/14 - $2.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ARRAY BIOPHARMA INC (ARRY)

array biopharma inc (ARRY) Related Bloomberg News

View More Bloomberg News

array biopharma inc (ARRY) Related Businessweek News

No Related Businessweek News Found

array biopharma inc (ARRY) Details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company’s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates, including Binimetinib, an MEK inhibitor for cancer; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company’s partnered clinical programs also comprise LY2606368, an Chk-1 inhibitor for cancer; GDC-0575, an Chk-1 inhibitor for cancer; ARRY-380/ONT-380, an HER2 inhibitor for breast cancer,; GDC-0994, an ERK inhibitor for cancer; and LOXO-101, an PanTrk inhibitor for cancer. It has collaborations with Celgene Corporation; Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

198 Employees
Last Reported Date: 08/15/14
Founded in 1998

array biopharma inc (ARRY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $548.8K
Co-Founder, Chief Operating Officer and Vice ...
Total Annual Compensation: $388.6K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $358.1K
Vice President, General Counsel and Secretary
Total Annual Compensation: $357.5K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $343.8K
Compensation as of Fiscal Year 2014.

array biopharma inc (ARRY) Key Developments

Array Biopharma, Inc. Announces Unaudited Earnings Results for the First Quarter Ended September 30, 2014; Announces Final Results from Phase 2 Trial of Binimetinib

Array BioPharma, Inc. announced unaudited earnings results for the first quarter ended September 30, 2014. For the quarter, the company reported total revenue of $6,069,000 against $14,228,000 a year ago. Loss from operations was $25,097,000 against $13,313,000 a year ago. Net loss was $27,593,000 against $15,680,000 a year ago. Net loss per share basic and diluted was $0.21 against $0.13 a year ago. The company announced final results from a Phase 2 trial of binimetinib in patients with advanced NRAS-mutant melanoma were presented at the ESMO Annual Meeting in September. Results from the 117 patient study showed median progression free survival (mPFS) of 3.6 months and objective response rate (ORR) of 14.5%, including one patient who achieved a complete response. These findings were consistent with previously disclosed interim results at the American Society of Clinical Oncology 2012 Annual Meeting. In addition, the median overall survival (mOS) of 12.2 months is encouraging for this patient population, which has a particularly poor prognosis. NEMO, a global Phase 3 trial currently enrolling patients with NRAS-mutant melanoma, is designed to measure the difference in mPFS between patients treated with binimetinib versus those treated with dacarbazine, a current standard of care. Adverse events in the Phase 2 study were generally mild to moderate. The most frequently observed adverse events included acneiform dermatitis, increased blood creatine phosphokinase and peripheral edema, which are consistent with previous results reported for the MEK inhibitor class. Three Phase 3 trials continue to evaluate selumetinib in patients with advanced cancers: second-line KRAS-mutant advanced or metastatic NSCLC (SELECT-1 /NCT01933932), differentiated thyroid cancer (ASTRA /NCT01843062) and metastatic uveal melanoma (SUMIT/NCT01974752). AstraZeneca has indicated that a regulatory filing from the uveal melanoma study is expected in 2015. In addition, AstraZeneca is conducting two new NSCLC studies involving selumetinib, one in combination with docetaxel followed by MEDI4736 (anti-PD-L1 antibody), the other in combination with AZD9291 (mutant-selective EGFR inhibitor).

Array BioPharma, Inc. to Report Q1, 2015 Results on Nov 04, 2014

Array BioPharma, Inc. announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on Nov 04, 2014

Array BioPharma, Inc., Q1 2015 Earnings Call, Nov 04, 2014

Array BioPharma, Inc., Q1 2015 Earnings Call, Nov 04, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARRY:US $3.76 USD +0.05

ARRY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.22 USD +0.05
Cytokinetics Inc $4.11 USD -0.03
Evotec AG €3.11 EUR +0.029
Exelixis Inc $1.76 USD +0.02
Progenics Pharmaceuticals Inc $6.77 USD +0.35
View Industry Companies

Industry Analysis


Industry Average

Valuation ARRY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARRAY BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at